<?xml version="1.0" encoding="UTF-8"?>
<p id="p0430">On the other hand, there are concerns regarding the capacity of CsA to increase ACE2 shedding and, consequently, to augment SARS-CoV-2 infection by increment the ACE2 upregulation.
 <xref rid="b1000" ref-type="bibr">
  <sup>200</sup>
 </xref> Furthermore, the CsA has serious side effects, which can cause hyperlipidaemia, gingival hyperplasia, nausea, vomiting, abdominal pain, headache, susceptibility to infections, triggering of cancer development, blood pressure increase, nephrotoxicity, and immune suppression. Its nephrotoxic effect is dose and duration dependent.
 <xref rid="b1005" ref-type="bibr">
  <sup>201</sup>
 </xref> Therefore, it is not clear whether CsA may mitigate or aggravate the SARS-CoV-2 infection, since there is no CsA clinical studies published up to now, even has been suggested that low-dose CsA can be useful for patients presenting SARS-CoV-2-induced cytokine storm.
 <xref rid="b1000" ref-type="bibr">
  <sup>200</sup>
 </xref>
</p>
